Prenatal exposure to selective serotonin reuptake inhibitors and childhood overweight at 7 years of age

Annals of Epidemiology

Volumn 23, Issue 11, 2013, Pages 681-687

  Grzeskowiak, Luke E ^a   Gilbert, Andrew L ^a   Sørensen, Thorkild I A ^b,c   Olsen, Jørn ^d   Sørensen, Henrik T ^e   Pedersen, Lars H ^d   Morrison, Janna L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Capital Region   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antidepressant agents adverse effects; Body mass index; Body weight drug effects; Depressive disorder drug therapy; Fetal development drug effects prenatal exposure delayed effects; Overweight; Pregnancy; Serotonin uptake inhibitors adverse effects

Indexed keywords

PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; FEMALE; FETUS DEVELOPMENT; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; OBESITY; PREGNANCY; PREGNANT WOMAN; PRENATAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL;

ANTIDEPRESSANT AGENTS/ADVERSE EFFECTS; BODY MASS INDEX; BODY WEIGHT/DRUG EFFECTS; DEPRESSIVE DISORDER/DRUG THERAPY; FETAL DEVELOPMENT/DRUG EFFECTS PRENATAL EXPOSURE DELAYED EFFECTS; OVERWEIGHT; PREGNANCY; SEROTONIN UPTAKE INHIBITORS/ADVERSE EFFECTS;

ANTIDEPRESSIVE AGENTS; BODY MASS INDEX; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DENMARK; DEPRESSIVE DISORDER; FEMALE; FETAL DEVELOPMENT; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MOTHERS; OVERWEIGHT; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 84885952411     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2013.08.005     Document Type: Article

References (49)

1. Bjørn A.-M.B., Nørgaard M., Hundborg H.H., Nohr E.A., Ehrenstein V. Use of prescribed drugs among primiparous women: an 11-year population-based study in Denmark. Clin Epidemiol 2011, 3:149-156.
2. Andrade S.E., Raebel M.A., Brown J., Lane K., Livingston J., Boudreau D., et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008, 198(2):194.e1-194.e5.
3. Grzeskowiak L.E., Gilbert A.L., Morrison J.L. Investigating outcomes following the use of SSRIs for treating depression in pregnancy: a focus on methodological issues. Drug Saf 2011, 34(11):1027-1048.
4. Lattimore K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal C.R., Vazquez D.M. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. JPerinatol 2005, 25(9):595-604.
5. Whitaker-Azmitia P.M. Serotonin and brain development: role in human developmental diseases. Brain Red Bull 2001, 56(5):479-485.
6. Blundell J.E., Halford J.C.G. Serotonin and appetite regulation: implications for the pharmacological treatment of obesity. CNS Drugs 1998, 9(6):473-495.
7. Halford J.C., Harrold J.A., Lawton C.L., Blundell J.E. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets 2005, 6(2):201-213.
8. Sargent B.J., Henderson A.J. Targeting 5-HT receptors for the treatment of obesity. Curr Opin Pharmacol 2011, 11(1):52-58.
9. Bouali S., Evrard A., Chastanet M., Lesch K.P., Hamon M., Adrien J. Sex hormone dependent desensitization of 5 HT1A autoreceptors in knockout mice deficient in the 5 HT transporter. Eur J Neurosci 2003, 18(8):2203-2212.
10. Li Q., Wichems C.H., Ma L., Van de Kar L.D., Garcia F., Murphy D.L. Brain region specific alterations of 5 HT2A and 5 HT2C receptors in serotonin transporter knockout mice. JNeurochem 2003, 84(6):1256-1265.
11. Li Q., Wichems C., Heils A., Lesch K.P., Murphy D.L. Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. JNeurosci 2000, 20(21):7888-7895.
12. Line S.J., Barkus C., Coyle C., Jennings K.A., Deacon R.M., Lesch K.P., et al. Opposingalterations in anxiety and species-typical behaviours in serotonin transporteroverexpressor and knockout mice. Eur Neuropsychopharmacol 2011, 21(1):108-116.
13. Lisboa S.F.S., Oliveira P.E., Costa L.C., Venancio E.J., Moreira E.G. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007, 80(1):49-56.
14. Üçeyler N., Schütt M., Palm F., Vogel C., Meier M., Schmitt A., et al. Lack of the serotonin transporter in mice reduces locomotor activity and leads to gender-dependent late onset obesity. Int J Obes 2010, 34:701-711.
15. Oberlander T.F., Gingrich J.A., Ansorge M.S. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 2009, 86(6):672-677.
16. Grzeskowiak L.E., Gilbert A.L., Morrison J.L. Long term impact of prenatal exposure to SSRIs on growth and body weight in childhood: Evidence from animal and human studies. Reprod Toxicol 2012, 34(1):101-109.
17. Chambers C.D., Anderson P.O., Thomas R.G., Dick L.M., Felix R.J., Johnson K.A., et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999, 104(5):e61-e66.
18. Lewis A.J., Galbally M., Opie G., Buist A. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry 2010, 44(5):482-487.
19. Wisner K.L., Bogen D.L., Sit D., McShea M., Hughes C., Rizzo D., et al. Does fetal exposure to SSRIs or maternal depression impact infant growth?. Am J Psychiatry 2013, 170(5):485-493.
20. Li J., Olsen J., Vestergaard M., Obel C., Baker J.L., Sørensen T. Prenatal stress exposure related to maternal bereavement and risk of childhood overweight. PLoS One 2010, 5(7):e11896.
21. Olsen J., Melbye M., Olsen S.F., Sørensen T., Aaby P., Nybo Andersen A.M., et al. The Danish National Birth Cohort-its background, structure and aim. Scand J Public Health 2001, 29(4):300-307.
22. The Anatomical Therapeutic Chemical Classification System With Defined Daily Doses 2003, World Health Organization, Collaborating Centre for Drug Statistics Methodology, World Health Organization, Geneva, Switzerland.
23. Cole T.J., Bellizzi M.C., Flegal K.M., Dietz W.H. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000, 320(7244):1240-1245.
24. Bech B.H., Nohr E.A., Vaeth M., Henriksen T.B., Olsen J. Coffee and fetal death: a cohort study with prospective data. Am J Epidemiol 2005, 162(10):983-990.
25. IOM (Institute of Medicine) and NRC (National Research Council) Weight Gain During Pregnancy: Reexamining the Guidelines 2009, The National Academies Press, Washington, DC. K.M. Rasmussen, A.L. Yaktine (Eds.).
26. Schmitz N., Kruse J., Tress W. Improving screening for mental disorders in the primary care setting by combining the GHQ-12 and SCL-90-R subscales. Compr Psychiatry 2001, 42(2):166-173.
27. Navarro P., Ascaso C., Garcia-Esteve L., Aguado J., Torres A., Martín-Santos R. Postnatal psychiatric morbidity: a validation study of the GHQ-12 and the EPDS as screening tools. Gen Hosp Psychiatry 2007, 29(1):1-7.
28. Tegethoff M., Greene N., Olsen J., Meyer A.H., Meinlschmidt G. Maternal psychosocial stress during pregnancy and placenta weight: evidence from a National Cohort Study. PLoS One 2010, 5(12):e14478.
29. Hogan J.W., Roy J., Korkontzelou C. Handling drop-out in longitudinal studies. Stat Med 2004, 23(9):1455-1497.
30. Cosgrove K.P., Mazure C.M., Staley J.K. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol Psychiatry 2007, 62(8):847-855.
31. Jovanovic H., Lundberg J., Karlsson P., Cerin Å., Saijo T., Varrone A., et al. Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 2008, 39(3):1408-1419.
32. Ren-Patterson R.F., Cochran L.W., Holmes A., Lesch K.P., Lu B., Murphy D.L. Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies. Cell Mol Neurobiol 2006, 26(4):753-778.
33. McCormick C.M., Smythe J.W., Sharma S., Meaney M.J. Sex-specific effects of prenatal stress on hypothalamic-pituitary-adrenal responses to stress and brain glucocorticoid receptor density in adult rats. Brain Res Dev Brain Res 1995, 84(1):55-61.
34. Szuran T.F., Plika V., Pokorny J., Welzl H. Prenatal stress in rats: effects on plasma corticosterone, hippocampal glucocorticoid receptors, and maze performance. Physiol Behav 2000, 71(3-4):353-362.
35. Weinstock M., Matlina E., Maor G.I., Rosen H., McEwen B.S. Prenatal stress selectively alters the reactivity of the hypothalamic-pituitary adrenal system in the female rat. Brain Res 1992, 595(2):195-200.
36. Murphy V.E., Gibson P.G., Giles W.B., Zakar T., Smith R., Bisits A.M., et al. Maternal asthma is associated with reduced female fetal growth. Am J Respir Crit Care Med 2003, 168(11):1317-1323.
37. Buss C., Lord C., Wadiwalla M., Hellhammer D.H., Lupien S.J., Meaney M.J., et al. Maternal care modulates the relationship between prenatal risk and hippocampal volume in women but not in men. JNeurosci 2007, 27(10):2592-2595.
38. Grzeskowiak L.E., Gilbert A.L., Morrison J.L. Prenatal exposure to selective serotonin reuptake inhibitors and risk of childhood overweight. JDev Orig Health Dis 2012, 3(4):253-261.
39. Matthews S. Early programming of the hypothalamo-pituitary-adrenal axis. Trends in Endocrinology and Metabolism 2002, 13(9):373-380.
40. Talge N., Neal C., Glover V. Antenatal maternal stress and long term effects on child neurodevelopment: how and why?. JChild Psychol Psychiatr 2007, 48(3/4):245-261.
41. Bjorntorp P. Neuroendocrine factors in obesity. JEndocrinol 1997, 155(2):193-195.
42. Cottrell E.C., Seckl J.R. Prenatal stress, glucocorticoids and the programming of adult disease. Front Behav Neurosci 2009, 3(19).
43. Andrews M.H., Matthews S.G. Programming of the hypothalamo-pituitary-adrenal axis: serotonergic involvement. Stress 2004, 7(1):15-27.
44. Oberlander T.F., Grunau R., Mayes L., Riggs W., Rurak D., Papsdorf M., et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 2008, 84(10):689-697.
45. Ingstrup K.G., Schou Andersen C., Ajslev T.A., Pedersen P., Sørensen T., Nohr E.A. Maternal distress during pregnancy and offspring childhood overweight. JObes 2012, 2012.
46. Pedersen L.H., Henriksen T.B., Vestergaard M., Olsen J., Bech B.H. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009, 339(231):b3569.
47. Andersen C. Validation of the height, weight and waist circumference in the 7-year follow-up in the Danish National Birth Cohort. 2012 [cited 5/8/2012]; Available from: http://www.ssi.dk/English/RandD/Research%20areas/Epidemiology/DNBC/Publications%20on%20Background%20and%20Methods/Validation%20of%20height%20weight%20and%20waist%20circumference.aspx.
48. Ertel K.A., Koenen K.C., Rich-Edwards J.W., Gillman M.W., Myer L. Maternal depressive symptoms not associated with reduced height in young children in a US Prospective Cohort Study. PLoS One 2010, 5(10):e13656.
49. Barnett L.M., Van Beurden E., Morgan P.J., Brooks L.O., Beard J.R. Childhood motor skill proficiency as a predictor of adolescent physical activity. JAdolesc Health 2009, 44(3):252-259.